Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DiAoXinXueKang capsule for primary hyperuricemia
ChiCTR-IPR-17014035Phase 4Recruiting
- Sponsor
- Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine
- Start
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of di'ao xinxuekang in Primary Hyperuricemia (2 arms), sponsored by Institute of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine. Primary endpoint: blood uric acid. Started Dec 2017; status: recruiting.
02
Drugs
di'ao xinxuekang
03
Conditions
Primary Hyperuricemia
Beyond the preview
Go deeper on ChiCTR-IPR-17014035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17014035.